Patient Safety Guide for Erdafitinib and Enfortumab Vedotin: What to Look for and What to Report to Your Healthcare Team

Download this PDF patient safety guide for a quick resource on signs and symptoms of specific AEs patients should look for while they are receiving erdafitinib or enfortumab vedotin.
person default
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Format: Adobe Acrobat (.pdf)
File Size: 80 KB
Released: January 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Downloadable slideset on updates in targeted therapy for HR-positive/HER2-negative metastatic breast cancer, from Clinical Care Options (CCO)

Komal Jhaveri, MD
Program Director
Released: June 7, 2022

Downloadable slideset on updates in targeted therapy for HR-positive/HER2-negative early-stage breast cancer, from Clinical Care Options (CCO)

Komal Jhaveri, MD
Program Director
Erica Mayer, MD, MPH
Released: June 6, 2022

PDF resource that serves as a helpful guide for healthcare professionals on CAR T-cell therapies in B-cell lymphomas, from Clinical Care Options (CCO)

Released: June 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings